Rate My Professor Nathan Bartlett

Professor Nathan Bartlett is a Professor in the School of Biomedical Sciences and Pharmacy, College of Health, Medicine and Wellbeing, at the University of Newcastle. He serves as Associate Dean for Industry and Engagement and leads the Viral Immunology and Respiratory Disease group at the Hunter Medical Research Institute. Bartlett obtained his PhD and Bachelor of Science with Honours from Deakin University. His career trajectory includes postdoctoral research positions at the Sir William Dunn School of Pathology, University of Oxford, focusing on viral vector vaccines, and in the Departments of Virology and Respiratory Medicine at Imperial College London. Appointed Lecturer at Imperial College London in 2011, he joined the University of Newcastle in 2015 and holds an honorary academic appointment at Imperial. As Associate Editor for the American Journal of Physiology - Lung, Cellular and Molecular Physiology, he contributes to the field through editorial oversight and serves as a member of the European Respiratory Society College of Experts.

Bartlett's research centers on viral immunology and the pathogenesis of virus-induced respiratory diseases, with a focus on rhinovirus, influenza, and coronaviruses in asthma and chronic obstructive pulmonary disease exacerbations. He developed the first mouse model of rhinovirus infection and airways disease exacerbation, published in Nature Medicine in 2008. Other notable publications include 'IL-33-Dependent type 2 inflammation during rhinovirus-induced asthma exacerbations in vivo' in the American Journal of Respiratory and Critical Care Medicine (2014) and editorship of Rhinovirus Infections: Rethinking Impact on Human Health and Disease (Elsevier, 2019). His innovations include innate immune stimulants delivered via nasal sprays, now in clinical trials for COVID-19 and common cold protection. Bartlett has led grants exceeding $22 million, supervised 17 PhD completions, and was awarded City of Newcastle Citizen of the Year in 2024 for pioneering COVID-19 treatments. His translational work bridges molecular virology, immunology, and clinical applications, influencing antiviral strategies and respiratory health management.